Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators..

Br J Dermatol. 2015 Oct;173(4):949-61. doi: 10.1111/bjd.14018.

PMID:
26149717
2.

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators..

Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10.

PMID:
26072109
3.

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8.

4.

Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.

Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group..

J Drugs Dermatol. 2014 Nov;13(11):1380-6.

PMID:
25607706
5.

A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin.

Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C; POWER study group..

Br J Dermatol. 2014 Dec;171(6):1508-16. doi: 10.1111/bjd.13191. Epub 2014 Oct 28.

PMID:
24934963
6.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group..

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

7.

Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guenther L, Kunynetz R, Nigen S, Vender R, Wasel N, Hsu MC, Szapary P.

J Drugs Dermatol. 2013 Oct;12(10):1122-9.

PMID:
24085047
8.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group..

Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.

PMID:
23769296
9.

Canadian consensus on skin barrier repair therapy in atopic dermatitis.

Thomas R, Landells I, Lynde C, Withers M, Weinstein M, Kunynetz R, Haber R, Balbul A, Dion PL.

J Cutan Med Surg. 2012 Mar-Apr;16 Suppl 1:S1-15. No abstract available.

PMID:
23577504
10.

A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial.

Poulin Y, Sanchez NP, Bucko A, Fowler J, Jarratt M, Kempers S, Kerrouche N, Dhuin JC, Kunynetz R.

Br J Dermatol. 2011 Jun;164(6):1376-82. doi: 10.1111/j.1365-2133.2011.10344.x. Epub 2011 May 20.

PMID:
21457209
11.

Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.

Kunynetz R, Carey W, Thomas R, Toth D, Trafford T, Vender R.

Eur J Dermatol. 2011 Jan-Feb;21(1):89-94. doi: 10.1684/ejd.2010.1185.

PMID:
21227890
12.

Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies.

Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J, Liu Y, Graeber M; Adapalene Lotion Study Group..

J Drugs Dermatol. 2010 Jun;9(6):639-46.

PMID:
20645525
13.

Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients.

Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu Y, Graeber M; Adapalene-BPO Study Group..

Br J Dermatol. 2009 Nov;161(5):1180-9. doi: 10.1111/j.1365-2133.2009.09209.x. Epub 2009 May 21.

PMID:
19466959
14.

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A.

Lancet. 2009 Feb 21;373(9664):633-40. doi: 10.1016/S0140-6736(09)60140-9. Epub 2009 Feb 11. Erratum in: Lancet. 2009 Apr 18;373(9672):1340. Lancet. 2010 Nov 6;376(9752):1542.

PMID:
19217154
15.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators..

Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6.

PMID:
18486740
16.

A review of systemic retinoid therapy for acne and related conditions.

Kunynetz RA.

Skin Therapy Lett. 2004 Mar;9(3):1-4. Erratum in: Skin Therapy Lett. 2005 Mar;10(2):9.

18.

Systemic antibiotic therapy for acne: a review.

Kunynetz R.

Skin Therapy Lett. 2002 May;7(5):3-7. Review.

PMID:
12223979
19.

The occurrence of mycosis fungoides in two patients with preexisting Hodgkin's disease.

Lipa M, Kunynetz R, Pawlowski D, Kerbel G, Haberman H.

Arch Dermatol. 1982 Aug;118(8):563-7. No abstract available.

PMID:
7103525
20.

Kaposi's sarcoma in recipients of renal transplants.

Harwood AR, Osoba D, Hofstader SL, Goldstein MB, Cardella CJ, Holecek MJ, Kunynetz R, Giammarco RA.

Am J Med. 1979 Nov;67(5):759-65. No abstract available.

PMID:
159624

Supplemental Content

Loading ...
Support Center